Journal article
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Abstract
PurposeRadium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. We provide straightforward and practical recommendations for European nuclear medicine centres to optimize radium-223 service provision.MethodsAn …
Authors
Du Y; Carrio I; De Vincentis G; Fanti S; Ilhan H; Mommsen C; Nitzsche E; Sundram F; Vogel W; Oyen W
Journal
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44, No. 10, pp. 1671–1678
Publisher
Springer Nature
Publication Date
September 2017
DOI
10.1007/s00259-017-3756-7
ISSN
1619-7070